---
layout: default
title: Sodium Chloride
parent: Model Prediction Only (L5)
nav_order: 422
evidence_level: L5
indication_count: 10
last_modified_at: 2026-10-15
description: "Sodium Chloride: predicted new indication Breast fibrocystic disease (evidence level L5). Approved use: Not stated in the SAHPRA registration data compiled for this report"
monitor_inn: "Sodium chloride"
predicted_indications: ["breast fibrocystic disease", "vulvovaginitis", "vulvitis", "postmenopausal atrophic vaginitis", "ulceration of vulva", "vulvar neoplasm", "blunt duct adenosis of breast", "apocrine adenosis of breast", "benign mammary dysplasia", "fat necrosis of breast"]
---

# Sodium Chloride
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Sodium Chloride: From Fluid and Electrolyte Replacement to Breast Fibrocystic Disease
{: .text-alpha }

## One-Sentence Summary

Sodium chloride is an electrolyte and fluid replenisher, registered in South Africa mainly in intravenous infusion, dialysis and related solutions.
The TxGNN model predicts it may be effective for **breast fibrocystic disease**, but **no clinical trials and no publications** support this prediction.
The high score most likely reflects proximity in the knowledge graph rather than a real therapeutic relationship.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the SAHPRA registration data compiled for this report (all 15 registrations have empty indication text) |
| Predicted New Indication | Breast fibrocystic disease |
| TxGNN Prediction Score | 96.79% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 15 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Sodium chloride is a standard electrolyte and fluid replenisher with no known pharmacological action on breast tissue.

Fibrocystic breast disease is a benign, hormone-sensitive breast condition. Sodium chloride has no recognised effect on the underlying biology. The assessment of this prediction is that it is not mechanistically supported. The high TxGNN score probably reflects shared gene or pathway neighbours in the knowledge graph.

The same pattern applies to the other top-ranked predictions. Several benign breast conditions (blunt duct adenosis, apocrine adenosis, benign mammary dysplasia, fat necrosis) form a cluster. Two of them have identical scores (95.75%), which points to a graph-structure artefact rather than independent signals. Predictions for vulvar and vaginal conditions (vulvovaginitis, vulvitis, postmenopausal atrophic vaginitis, vulvar ulceration, vulvar neoplasm) have at most a supportive role, such as saline cleansing or compresses, and no disease-modifying activity.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available for breast fibrocystic disease.

For reference, the only publication retrieved across the top ten predictions concerns vulvovaginitis (not the lead indication):

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [33860751](https://pubmed.ncbi.nlm.nih.gov/33860751/) | 2021 | Case report | Int J Clin Pharmacol Ther | Chills, fatigue, chest distress and raised WBC, neutrophils, CRP and PCT after a terconazole vaginal suppository. It is an adverse-reaction report, not a treatment study, and does not support benefit from sodium chloride. |

## South Africa Market Information

Sodium chloride is registered in 15 valid single-ingredient products. Indication text was not available for any of them. Essential Medicines List status was not available in the data compiled for this report. Main registrations (5 of 15):

| Registration Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| Z/24/107 | Neonatal maint solution spb0008 | Infusion | Not stated |
| 36/34/0484 | Combibic Electrolyte Sol No/Potass 500 | Infusion | Not stated |
| D/24/208 | Ringer-lactate 3000ml afb2327 | Infusion | Not stated |
| 34/24/0371 | Euromed Lactated Ringer's Solution | Solution | Not stated |
| E875 (ACT 101/1965) | Sabax Plasmalyte B (1000Ml) | Infusion | Not stated |

All registered forms are infusions or solutions. Other registrations include dialysis, haemofiltration and cardioplegic solutions, and one veterinary product.

## Safety Considerations

**Drug Interactions** (2 moderate-level interactions):
- Tolvaptan (Moderate)
- Lithium carbonate (Moderate)

For warnings and contraindications, please refer to the SAHPRA-approved Professional Information (PI). Report adverse drug reactions to SAHPRA.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests only on a model score, with no clinical trials, no supporting literature and no plausible mechanism. The ten top-ranked predictions all have L5 evidence, and the lead indication is not supported by any identifiable biology.

**To proceed, the following is needed:**
- Any clinical or preclinical evidence linking sodium chloride to the predicted condition
- Mechanism of action data
- SAHPRA package insert warnings and contraindications, which are currently missing and block safety screening
- Approved indication text for the registered products
- Assessment of route compatibility and similarity to the original indication
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

